Entecavir Good Manufacturer supply High Quality 142217-69-4
- Molecular Formula:C12H15N5O3
- Molecular Weight:277.283
- Appearance/Colour:white to off-white/yellow crystalline powder
- Melting Point:249-252 °C
- Refractive Index:1.837
- Boiling Point:734.2 °C at 760 mmHg
- PKA:14.22±0.60(Predicted)
- Flash Point:397.9 °C
- PSA：130.05000
- Density:1.81 g/cm3
- LogP:-0.24660
Entecavir (142217-69-4) Usage
Entecavir is a cyclopentyl guanosine analog launched for the once-daily oral treatment of chronic hepatitis B virus (HBV) infection, and it is the third nucleoside or nucleotide analog to be marketed for this indication. Lamivudine, a deoxythiacytosine analog, and adefovir dipivoxil, a nucleotide analog, have been marketed since 1998 and 2002, respectively. Entecavir and adefovir are specifically indicated for HBV, whereas lamivudine is indicated for both HBV and HIV infections.
How to get the best price on Entecavir?
Zibo Hangyu Biotechnology Development Co., Ltd is a quality supplier and manufacturer of Entecavir . You can buy high quality, low price Entecavir 142217-69-4 here.
Zibo Hangyu Biotechnology Development Co., Ltd. is a comprehensive chemical enterprise focusing on fine chemical products and pharmaceutical intermediates, integrating research and development, production and sales. The company is equipped with advanced equipment quality inspection and research center. At the same time, the company has excellent talents with rich experience in process development and quality control. To provide customers with total solutions from raw material processing to chemical synthesis systems. The company has established a standardized and perfect quality standard system to provide stable and high quality production and service.
Milestones
- 2012yearThe company was founded, began to engage in the production and supply of chemical raw materials
- 2014yearExpand the scale of production, pharmaceutical raw materials production workshop was established
- 2016yearCooperated with domestic and foreign chemical platforms to promote self-produced and high-end pharmaceutical intermediates
- 2019yearIn recent years to participate in the international pharmaceutical raw materials exhibitions
- 2023yearBusiness continues to expand, Production and Sales teams continue to grow
- 2026yearPlans to set up foreign branches
